co
despit still
share trade yesterday vs attribut
perform disappoint guidanc market feel somewhat blind-
side tender certain china provinc impact medic busi
develop late quarter think stock weak opportun
continu view share attract reiter overweight rate
disappoint guidanc context believ guidanc appropri
risk-adjust bd guid compar constant currenc sale growth
incorpor on-going headwind drug-coat balloon btk
approv assum china tender price ep guidanc reflect underli
growth adjust gore fx seem
build bit room mind tariff adjust ep
guidanc even headwind level
continu view bd underli durabl growth compani
compani host investor day may discuss outlook
final year bard integr come close believ bd built
diversifi base done larg transform deal look
supplement exist infrastructur technology-ori tuck-in deal
continu build sharehold valu support durabl growth outlook
reduc fiscal year ep estim mainli
reflect greater impact fx rate well impact china tender
maintain price target cy ep estim
versu prior estim materi chang due ep cadenc given
upsid rel price target continu believ share warrant
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay co
co
overweight believ bd continu
success integr bard achiev plan
revenu cost synergi view recent
pullback share drug-coat balloon
concern overreact see upsid
share consid bd sale
ep growth profil compani view
valuat attract
upsid case could driven better-than-
bard acquisit improv overal
growth rate btk indic and/or favor
fda letter updat june panel
downsid case could driven foreign
exchang stronger usd could pressur
expect sale legaci bard busi
slowdown emerg market growth inabl
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
barclay co
result solid sale come street
estim compar constant currenc sale growth ep beat
street expect howev issu somewhat disappoint
sale ep guidanc rel expect said think guidanc
appropri risk adjust thing consid still reflect compani
sale growth underli growth adjust gore
fx tariff view unchang rate overweight
addit detail quarter
million except per share data chang sale constant currenc basi unless otherwis note
sale ep expect
urolog critic constant currenc growth expect
driven acut urolog continu strength temperatur manag sale
bioscienc constant currenc growth driven research clinic
instrument sale along research reagent
ep guidanc street/w expect
pre-releas bloomberg barclay key driver differ
expect fx headwind versu previou manag commentari
sale growth guidanc slightli
street expect guidanc includ price headwind
includ pressur china tender process deliveri md well
dcb sale expect lower y/i anniversari
fda letter march
medic deliveri system md china sale overal weaker
expect price pressur basic medic devic due china tender
sale compar constant currenc basi growth
fairli balanc medic life scienc intervent
gross margin y/i acceler revenu growth continu
improv synergi captur currenc headwind abat off-set
margin pressur lower dcb sale raw materi
sg sale y/i reflect disciplin spend
continu achiev bard cost synergi
 sale y/i
oper margin y/i
adjust tax rate
adjust ep y/i currency-neutr basi
manag expect compar constant currenc revenu growth due softwar upgrad within medic
manag solut like push revenu price headwind china tender dcb declin anniversari
fda letter impact ep expect rang
bd expect report sale growth inclus fx headwind compar constant currenc sale growth
expect reflect growth divis bd medic life scienc intervent
adjust ep expect includ headwind gore royalti fx tariff
actualsal mrptdc-fxnbd management compar fx neutral basisyoy changebd barclay co
link note click titl link barclay live
forlenza pass baton polen expect
model avail barclay live upon request
model avail barclay live
link click
barclay co
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
